Nilotinib Stada 200 Mg Cápsulas (Nilotinib)

Nilotinib blocks the ATP‑binding site of the BCR‑ABL fusion protein, halting its tyrosine kinase activity. This inhibition stops downstream signaling that drives uncontrolled cell growth, leading to reduced proliferation of malignant leukemic cells and promoting apoptosis.

The exact dose and schedule of nilotinib are determined by the prescribing physician based on the patient’s specific diagnosis, disease stage, prior therapies, renal and hepatic function, and potential drug interactions. Dosing is individualized and should follow the clinician’s written order.

Safety of nilotinib in pregnancy and lactation has not been established. It should only be used if the potential therapeutic benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor with higher potency and selectivity than first‑generation agents like imatinib. It is often used when patients are resistant or intolerant to imatinib, offering deeper molecular responses but requiring careful monitoring for cardiac and metabolic adverse effects.

Store Nilotinib Stada 200 Mg Cápsulas at ambient temperature, preferably below 25 °C. Keep the capsules in the original blister pack or container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Nilotinib capsules are taken orally, usually with a low‑fat meal to improve absorption. Patients should swallow the capsule whole with water, avoid taking antacids or supplements containing aluminum or magnesium within two hours, and follow the dosing schedule prescribed by their clinician.

The most serious risks associated with nilotinib include QT interval prolongation, which can lead to serious cardiac arrhythmias, severe hepatic toxicity, and pancreatitis. Patients should be monitored regularly with ECGs, liver function tests, and pancreatic enzyme assessments.

Nilotinib should not be used in patients with known hypersensitivity to the drug, those with a history of prolonged QT interval, severe hepatic impairment, or uncontrolled electrolyte abnormalities. Caution is also advised for patients taking other QT‑prolonging medications.